Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk) | Zendy

Saima Rathore | Zendy; Suyash Mohan | Zendy; Spyridon Bakas | Zendy; Chiharu Sako | Zendy; Chaitra Badve | Zendy; Sarthak Pati | Zendy; Ashish Singh | Zendy; Dimitrios Bounias | Zendy; Phuc Ngo | Zendy; Hamed Akbari | Zendy; Aimilia Gastounioti | Zendy; Mark Bergman | Zendy; Michel Bilello | Zendy; Russell T. Shinohara | Zendy; Paul A. Yushkevich | Zendy; Donald M. O’Rourke | Zendy; Andrew E. Sloan | Zendy; Despina Kontos | Zendy; MacLean P. Nasrallah | Zendy; Jill S. BarnholtzSloan | Zendy; Christos Davatzikos | Zendy

Open Access

Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk)

Author(s) -

Saima Rathore,

Suyash Mohan,

Spyridon Bakas,

Chiharu Sako,

Chaitra Badve,

Sarthak Pati,

Ashish Singh,

Dimitrios Bounias,

Phuc Ngo,

Hamed Akbari,

Aimilia Gastounioti,

Mark Bergman,

Michel Bilello,

Russell T. Shinohara,

Paul A. Yushkevich,

Donald M. O’Rourke,

Andrew E. Sloan,

Despina Kontos,

MacLean P. Nasrallah,

Jill S. BarnholtzSloan,

Christos Davatzikos

Publication year - 2020

Publication title -

neuro-oncology advances

Language(s) - English

Resource type - Journals

ISSN - 2632-2498

DOI - 10.1093/noajnl/vdaa128

Subject(s) - glioma , idh1 , isocitrate dehydrogenase , idh2 , phenomics , imaging biomarker , cancer , cancer research , pathology , medicine , oncology , magnetic resonance imaging , biology , radiology , genomics , mutant , biochemistry , genome , gene , enzyme

Gliomas represent a biologically heterogeneous group of primary brain tumors with uncontrolled cellular proliferation and diffuse infiltration that renders them almost incurable, thereby leading to a grim prognosis. Recent comprehensive genomic profiling has greatly elucidated the molecular hallmarks of gliomas, including the mutations in isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ), loss of chromosomes 1p and 19q (1p/19q), and epidermal growth factor receptor variant III (EGFRvIII). Detection of these molecular alterations is based on ex vivo analysis of surgically resected tissue specimen that sometimes is not adequate for testing and/or does not capture the spatial tumor heterogeneity of the neoplasm.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research